BRAF and neoplasm: On the basis of this rationale, our group and others showed that retreatment with anti-EGFR monoclonal antibodies (mAbs) alone or in combination with chemotherapy or immunotherapy has clinically relevant antitumor activity in a subset of patients with plasma circulating tumor DNA (ctDNA) RAS/BRAF wild-type (WT) tumors [13,14,15,16,17,18].